Traws Pharma, Inc.
TRAWAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Neutral | Aug 18, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 18, 2026 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Jun 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2026 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.21| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.16 | $-0.34 | — | — |
| May 15, 2026 | $-0.53 | $-0.92 | — | — |
| Apr 15, 2026 | $-0.82 | $-1.91 | — | — |
| Nov 13, 2025 | $-0.34 | $-9.16 | — | $60.0K |
| Aug 14, 2025 | $-0.11 | $-8.75 | $2.7M | $60.0K |
| May 15, 2025 | $2.09 | $-8.04 | $57.0K | $60.0K |
| Mar 31, 2025 | $0.96 | $-0.10 | $56.0K | $60.0K |
| Nov 15, 2024 | $-8.81 | $-6.25 | $57.0K | $60.0K |
News
Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results and provided recent business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and April 2026 financing.